New Injection Targets ‘Hidden’ Belly Fat by Triggering Fat-Cell Death, Early Trial Data Show

An experimental injection that destroys fat cells rather than shrinking them has shown it can reduce one of the most dangerous types of fat in the human body — the deep abdominal deposits wrapped around internal organs that are strongly linked to diabetes, heart disease and metabolic illness — according to data presented by researchers at a major European diabetes conference.

The drug, called CBL-514 and developed by the Taiwanese firm Caliway Biopharmaceuticals, was tested in two small phase 2 clinical trials. A new analysis of MRI scans from a subset of participants found that people who received the injections into their lower abdomen lost a significant amount of visceral fat — the “hidden” fat packed around organs deep inside the belly — while participants who received a placebo gained visceral fat over the same period.

The findings were presented on October 1 at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, by Dr W. Timothy Garvey of the University of Alabama at Birmingham and Yu-Fang Ling of Caliway Biopharmaceuticals, according to Science News and news-medical.net. Four weeks after the course of treatment ended, the average volume of visceral fat in the treated group had fallen by 12.01 per cent, while it had increased by 5.68 per cent in the placebo group, SciTechDaily reported.

The research marks a potential shift in how medicine approaches fat reduction. For decades, the standard strategy for losing weight has been to shrink fat cells through diet, exercise or appetite-suppressing drugs such as the GLP-1 medicines that have transformed obesity treatment in recent years. But shrunken fat cells remain in the body, poised to expand again the moment calorie intake rises — one reason, researchers say, so many people regain weight after a diet ends.

CBL-514 takes a more permanent approach. It selectively triggers apoptosis — the biological programme through which cells self-destruct — inside adipocytes, the body’s fat cells, while leaving neighbouring cells unharmed, according to the researchers. In other words, the drug does not just deflate fat cells; it marks them for elimination.

What the New Analysis Found

The new data came from a re-analysis of MRI scans collected during two phase 2 trials, codenamed CBL-0204 and CBL-0205, which had originally been designed to test the drug’s effect on subcutaneous fat — the pinchable layer of fat that sits directly beneath the skin. Garvey and Ling used the available scans to look deeper, at the visceral fat hidden around the organs, according to SciTechDaily.

The analysis covered 40 participants whose body mass index ranged from 22 to 30, spanning healthy weight to overweight. Twenty-three received CBL-514 and 17 received a placebo. Participants got injections into the lower abdomen every three weeks for up to 12 weeks, at doses of up to 600 milligrams, according to Fox News. The number of injections each person received depended on the thickness of their abdominal fat; as the fat layer shrank, fewer injections were needed.

At the start of the study the two groups were evenly matched: the treated group held an average of 642.5 millilitres of visceral fat, while the placebo group averaged 677.4 millilitres, Science News reported. Four weeks after the final treatment, those who had received the drug had lost an average of nearly 71 millilitres of that fat — a decrease of about 12 per cent — while the placebo group had gained an average of about 31 millilitres, a rise of nearly 6 per cent.

The trial team had already established that the drug reduces the fat directly under the skin. In the earlier phase 2 results, 69.6 per cent of treated participants had lost at least 150 millilitres — roughly five US fluid ounces — of subcutaneous fat at the eight-week follow-up, compared with none of those who received the placebo, according to SciTechDaily.

Why Visceral Fat Matters So Much

Visceral fat is the internal packing material deep inside the abdomen, surrounding the liver, intestines and other vital organs. Unlike the fat under the skin, it cannot be seen or pinched, and it cannot be removed by procedures such as liposuction that reshape the belly. It is also biologically active: it secretes inflammatory molecules and hormones that influence metabolism, promote insulin resistance, and help drive type 2 diabetes and cardiovascular problems, including heart attacks and strokes.

Research published in March by the American Heart Association found that visceral fat had a stronger association with the risk of heart failure than body mass index — a reminder, as Fox News noted, that the standard weight-and-height ratio misses much of the real risk. A person can have a normal BMI and still carry a dangerous burden of fat around their organs.

That is what makes the CBL-514 results potentially significant. The most effective weight-loss drugs of the current era — the GLP-1 receptor agonists such as tirzepatide and semaglutide — reduce appetite and drive down overall weight, but they shrink fat cells rather than destroying them. Many people who stop taking these drugs regain much of the weight, a pattern familiar from decades of dieting.

Here the early animal data are intriguing. In preclinical studies on rats, CBL-514 reduced weight and both subcutaneous and visceral fat, according to news-medical.net. More weight was lost when the drug was given alongside the GLP-1 drug tirzepatide. And in a striking finding, rats given both CBL-514 and tirzepatide regained less weight after tirzepatide was stopped than rats given tirzepatide alone. The hypothesis is that killing off some fat cells limits how much fat the body can reaccumulate — but the researchers are careful to stress that this remains a hypothesis, and that human research is needed to prove it.

How the Drug Works

Most anti-obesity medicines act on the brain, the gut or the body’s energy balance. CBL-514 acts directly on the tissue itself. The injected compound selectively induces apoptosis in adipocytes — the death programme that cells use to dismantle themselves safely — while sparing the muscle, skin and connective tissue around them, according to the trial team.

Apoptosis is a normal, orderly process; the body uses it constantly to remove worn-out cells without triggering inflammation. The idea of harnessing it against fat cells is elegant, but it is also why the drug’s safety will be scrutinised so carefully. Destroying cells on command is a powerful mechanism, and regulators will want to see extensive evidence that the destruction stays precisely where it is aimed — and that it does not produce longer-term metabolic surprises. The trial programme is still at phase 2, an early stage in which drugs are typically tested in dozens or hundreds of patients, and approval for general use would be years away even if the larger trials succeed.

The drug is being developed by Caliway Biopharmaceuticals, based in New Taipei City, Taiwan. It has not yet received regulatory approval anywhere in the world, and none of the available reporting describes the full safety profile from the phase 2 programme in detail — a gap that larger trials are designed to fill.

Analysis: Why It Matters

The excitement around CBL-514 is best understood against the backdrop of the obesity-treatment revolution of the past several years. GLP-1 drugs turned weight loss from a lifestyle aspiration into a pharmaceutical reality for millions of people — but they also exposed two of the field’s oldest frustrations. The first is regain: stop the drug, and the hunger returns, and the fat cells that were merely shrunken start filling back up. The second is that the most dangerous fat is not the fat people can see. A person can lose impressive amounts of weight and still be told by their doctor that their metabolic risk has barely moved.

CBL-514 attacks both problems at the point where they meet. If the mechanism truly removes fat cells permanently, it offers something no current therapy does: a one-way ratchet. Diet shrinks cells; this drug deletes them. That is why the regain finding in rats matters more, in some ways, than the headline 12 per cent figure. The 12 per cent comes from a tiny MRI sub-study of 40 people, and small trials are notorious for producing results that shrink when tested at scale. The regain hypothesis, if it holds up in humans, would represent a genuine conceptual advance — a treatment that does not just lose the weight but changes the body’s capacity to find it again.

There are reasons for caution that go beyond the usual small-trial caveats. Apoptosis is safe when it happens cell by cell under the body’s own control; induced apoptosis in millions of fat cells at once is a different proposition, and fat tissue is not inert padding. It is an endocrine organ. Removing a meaningful share of it could have consequences — hormonal, metabolic, cosmetic — that only emerge in much larger, longer studies. The researchers’ selectivity claim (fat cells only, neighbours untouched) is precisely the finding that needs the hardest scrutiny, because the history of weight-loss drugs is littered with compounds that looked beautifully targeted in small trials and turned out to be less discriminating later.

The geography of the development is also worth noticing. The biggest obesity-drug pipelines are dominated by a handful of American and Danish giants; CBL-514 comes from a Taiwanese biotech firm, and the data were unveiled not at an obesity society meeting but at a diabetes congress — a quiet signal of where the company sees the drug’s real value proposition. If visceral fat, the driver of diabetes and cardiovascular risk, is the true target, then CBL-514 may be pitching itself less as a weight-loss drug and more as a metabolic medicine. That framing matters for regulators, insurers and ultimately patients: destroying belly fat to lower diabetes risk is a very different story from a cosmetic injection, and it will be judged by very different standards.

None of this should be read as a promise. The drug is experimental, the trials are small, and the history of fat-destroying injections includes cautionary tales — older injectable fat dissolvers produced uneven results and occasional serious side effects. What CBL-514 has done is demonstrate, in a controlled human trial with MRI-measured endpoints, that the apoptosis approach can move the most dangerous kind of fat in the right direction. That is a genuine scientific milestone, not a product launch. The distance between those two things is measured in years and thousands of patients.

What to Watch Next

1. Phase 3 trials and scale. The phase 2 data rest on 40 MRI scans in the visceral-fat sub-analysis. Everything about this drug’s future — efficacy, safety, commercial viability — depends on large, multi-centre phase 3 trials with thousands of patients and longer follow-up.
2. The full safety picture. The published summaries describe an early-stage programme. Regulators and investors will be watching for detailed adverse-event data: local injection-site reactions, any sign of effects beyond the targeted fat layer, and longer-term metabolic changes.
3. The weight-regain question. The rat finding — less regain after stopping tirzepatide when CBL-514 was co-administered — is the most commercially explosive claim in the data package. It has not been shown in humans. A trial designed specifically to test maintenance of weight loss after GLP-1 discontinuation would be the obvious next step.
4. Regulatory positioning. Will Caliway pursue CBL-514 as a diabetes/metabolic medicine, an obesity drug, or an aesthetic fat-reduction product? Each route carries a different regulatory bar, a different market and a different risk calculus — and the company’s choice will say a lot about how confident it is in the visceral-fat data.
5. The 2026 obesity-drug landscape. The year has already brought a wave of next-generation approaches — combination therapies, longer-acting compounds, and now cell-targeting injections. CBL-514 is the most conceptually radical entry yet: not less hunger, not faster metabolism, but fewer fat cells. If the mechanism validates, expect fast followers.

Sources

• Science News: “An experimental drug kills fat cells, rather than shrinking them”
• Fox News: “New belly fat injection cuts dangerous fat surrounding organs by 12% in early human trial”
• SciTechDaily: “New Fat-Dissolving Shot Cuts Hidden Visceral Fat in Early Human Trials”